Navigation Links
OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
Date:10/13/2008

ncer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Increased clusterin production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, renal, pancreatic, anaplastic large cell lymphoma and colon cancers and melanoma. Increased clusterin production is linked to faster rates of cancer progression, treatment resistance and shorter survival duration. OGX-011 is being evaluated in five Phase 2 clinical trials, each of which has completed patient enrollment. Interim study results have previously been presented for each of the five clinical trials.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 and SN2310 are in Phase 1 clinical development; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at http://www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning agreements with the FDA regarding endpoints and clinical trial design and anticipated clinical and other product development activities and timing of these activities. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumpti
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
2. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
3. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
4. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. OncoGenex increases economic interest in lead cancer drug OGX-011
7. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
8. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
9. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
10. Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation
11. Realtime Achieves ISO 13485:2003 Certification Targeting BioTech Quality Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Texas (PRWEB) September 23, 2014 ... the current state of the Phenolic Resin industry ... overview of the industry, including definitions, applications and ... domestic market analysis are provided with a focus ... the market. A comparison between the international and ...
(Date:9/23/2014)... 2014 Research and Markets  has ... for Research and IVD Applications (Mass Spectrometry, Chromatography, ... their offering. This report defines ... in their research use and in IVD.  Proteomics ... of the structure and function of proteins. This ...
(Date:9/23/2014)... September 23, 2014 Proove Biosciences ... presented industry leading research and data on the association ... the American Academy of Pain Management’ s ... Phoenix, Arizona at the , Proove Biosciences ... gender and genetic predisposition to opioid misuse risk in ...
(Date:9/23/2014)... , Sept. 23, 2014  Age Defying Dermatology ... Noodleman , has become one of the first clinics ... only "picoseconds" aesthetic laser for tattoo removal. The treatment ... better results. "For years, tattoo removal has been a ... Dr. Noodleman. "This is an opportunity to erase tattoo ...
Breaking Biology Technology:Phenolic Resin Industry (International, China) Development Policy and Plan Now Available at ReportsnReports.com 2Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 2Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 3Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 4Proove Biosciences Will Be Exhibiting I.M.P.L.O.R.E Study at the American Academy of Pain Management 25th Annual Meeting 2Proove Biosciences Will Be Exhibiting I.M.P.L.O.R.E Study at the American Academy of Pain Management 25th Annual Meeting 3Age Defy Now Offers World's Most Advanced Technology for Tattoo Removal 2
... DURHAM, N.C. -- Duke University and United States Army ... and diaper rash preventative can be made to produce ... Duke adjunct physics professor Henry Everitt, chemistry professor Jie ... that adding sulfur to ultra-fine powders of commonplace zinc ...
... 17 St. Joseph,s Hospital and Medical Center, Phoenix, today ... Clinical InfoNET videoconferencing system to connect specialist ... This program will include the Barrow Neurological Institute, as ... , With the objective of ...
... Calif., Dec. 17 Senetek PLC,(OTC Bulletin Board: SNKTY), ... that target the science of healthy aging, today,announced that ... proposed at the Annual General Meeting of Shareholders held ... "We are pleased with the results of the ...
Cached Biology Technology:Duke researchers coax bright white light from unexpected source 2Duke researchers coax bright white light from unexpected source 3St. Joseph's Hospital and Medical Center to Utilize Clinical InfoNET System for Physicians 2St. Joseph's Hospital and Medical Center to Utilize Clinical InfoNET System for Physicians 3Senetek PLC Announces 2008 Annual General Meeting Voting Results 2
(Date:9/23/2014)... SANTA CLARA, California , 23 de ... anuncia el lanzamiento del Sistema 1290 Infinity ... serie 1200 de Infinity en su portafolio ... los técnicos, científicos y directores de laboratorio ... calidad analítica excepcional, facilidad de uso y ...
(Date:9/23/2014)... immediate welfare consequences of removing infant chimpanzees from their ... long-term impacts of this type of early life experience. ... observed 60 chimpanzees and concluded that those who were ... by humans as pets or performers are likely to ... multi-institutional research project, published today in the open-access journal ...
(Date:9/22/2014)... Chicago have shown that after a long stay in ... pathogenic microbe species remain behind in patients, intestines. The ... can become deadly when provoked by conditions that mimic ... published in mBio , the online open-access journal ... better monitoring and treatment of ICU patients who can ...
Breaking Biology News(10 mins):Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 2Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 3Chimpanzees raised as pets or performers suffer long-term effects on their behavior 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3
... (FiO), the 91st Annual Meeting of the Optical Society ... San Jose, Calif., alongside Laser Science XXIII, the annual ... Science. Reporters interested in obtaining a badge to ... cmorri@osa.org . FiO RESEARCH HIGHLIGHTS ...
... Makes Tuna That Tastes Good, But These Bluefin Are ... bluefin tuna caught in the Gulf of Maine has ... University of New Hampshire have found by analyzing detailed ... Fishermans Co-op. The findings, published this week in Fishery ...
... the social habits of living cells an innovation ... help fight diseases such as cancer and diabetes. ... six countries, The Manchester Centre for Integrative Systems Biology ... research into an emerging field of science and engineering ...
Cached Biology News:Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 2Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 3Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 4Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 5Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 6Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 7Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 8Condition of bluefin tuna in gulf of maine is declining 2Condition of bluefin tuna in gulf of maine is declining 3Social habits of cells may hold key to fighting diseases 2
Request Info...
... The Cetac Ultrasonic Nebulizers are available in two ... difference between these two models is that the ... to create a drier aerosol for improved detection ... detection limits for a range of elements by ...
... inhibition of RNase A-type ribonucleases Product Description: ... nonhuman origin that binds noncovalently and inactivates ... B, and C). It does not interfere ... or CL3. QIAGEN RNase Inhibitor inhibits greater ...
... is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
Biology Products: